|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-4-6
|
|
pubmed:abstractText |
We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44-142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-10496285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-10653879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-11309331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-14686732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-14996626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-15072451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-1993014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-7928487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-7931469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-8559376,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-8814163,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-9396393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-9607424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16524945-9776413
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1522-8517
|
|
pubmed:author |
pubmed-author:AbreyLauren ELE,
pubmed-author:BayerRobertR,
pubmed-author:CairncrossJ GregoryJG,
pubmed-author:ChildsBarrett HBH,
pubmed-author:DeAngelisLisa MLM,
pubmed-author:DouglasStewartS,
pubmed-author:FinlayJonathan LJL,
pubmed-author:ForsythPeterP,
pubmed-author:GardnerSharonS,
pubmed-author:KaminerLynneL,
pubmed-author:MacdonaldDavid RDR,
pubmed-author:NimerStephen DSD,
pubmed-author:PaleologosNinaN,
pubmed-author:PetersonKendraK,
pubmed-author:RamsayDavid ADA,
pubmed-author:RosenfeldStevenS,
pubmed-author:SalzmanDonnaD,
pubmed-author:SmithAnne MAM,
pubmed-author:SwinnenLodeL,
pubmed-author:WeaverSusanS,
pubmed-author:WeissA BAB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16524945-Adolescent,
pubmed-meshheading:16524945-Adult,
pubmed-meshheading:16524945-Aged,
pubmed-meshheading:16524945-Antineoplastic Agents,
pubmed-meshheading:16524945-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16524945-Brain Neoplasms,
pubmed-meshheading:16524945-Combined Modality Therapy,
pubmed-meshheading:16524945-Disease-Free Survival,
pubmed-meshheading:16524945-Female,
pubmed-meshheading:16524945-Follow-Up Studies,
pubmed-meshheading:16524945-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16524945-Humans,
pubmed-meshheading:16524945-Lomustine,
pubmed-meshheading:16524945-Male,
pubmed-meshheading:16524945-Middle Aged,
pubmed-meshheading:16524945-Oligodendroglioma,
pubmed-meshheading:16524945-Procarbazine,
pubmed-meshheading:16524945-Survival Analysis,
pubmed-meshheading:16524945-Thiotepa,
pubmed-meshheading:16524945-Treatment Outcome,
pubmed-meshheading:16524945-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
|
|
pubmed:affiliation |
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. abreyl@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
